Sections - Tester page
CCRM Nordic was established to address the critical infrastructure gap for ATMP development and manufacturing in the Nordics.
Accordion title
CCRM Nordic was established to address the critical infrastructure gap for ATMP development and manufacturing in the Nordics. We are bridging this gap with our operational development labs and our upcoming large-scale development and GMP manufacturing facility.
-
Accordion title
CCRM Nordic was established to address the critical infrastructure gap for ATMP development and manufacturing in the Nordics. We are bridging this gap with our operational development labs and our upcoming large-scale development and GMP manufacturing facility.
-
Accordion title
CCRM Nordic was established to address the critical infrastructure gap for ATMP development and manufacturing in the Nordics. We are bridging this gap with our operational development labs and our upcoming large-scale development and GMP manufacturing facility.
Stay Connected with CCRM Nordic
Join our network for exclusive insights, career opportunities, and thought leadership content from Nordic industry experts.
- 4000+ professionals
- Direct communication
- Weekly insights
Custom CTA
CTA Image
Our facility brings every aspect of ATMP development under one roof. It’s a place where you grow your expertise and develop your professional network while directly contributing to the therapies of the future.
FAQ section
Our facility brings every aspect of ATMP development under one roof. It’s a place where you grow your expertise and develop your professional network while directly contributing to the therapies of the future.
-
FAQ title
Our facility brings every aspect of ATMP development under one roof. It’s a place where you grow your expertise and develop your professional network while directly contributing to the therapies of the future.
-
FAQ title
Our facility brings every aspect of ATMP development under one roof. It’s a place where you grow your expertise and develop your professional network while directly contributing to the therapies of the future.
-
FAQ title
Our facility brings every aspect of ATMP development under one roof. It’s a place where you grow your expertise and develop your professional network while directly contributing to the therapies of the future.
-
FAQ title
Our facility brings every aspect of ATMP development under one roof. It’s a place where you grow your expertise and develop your professional network while directly contributing to the therapies of the future.
Our facility brings every aspect of ATMP development under one roof. It’s a place where you grow your expertise and develop your professional network while directly contributing to the therapies of the future.
Name of the quoted person
Role or other information of the quoted person
Image & Text section
While we work with all ATMP types, we have established a platform for immune cell therapies and are building platforms for lentiviral vector production and iPSC-derived cell therapies.
Image & Text section
While we work with all ATMP types, we have established a platform for immune cell therapies and are building platforms for lentiviral vector production and iPSC-derived cell therapies.
Latest news
See all News-
Poster: ActiveMax µBeads as a cell-free off-the-shelf...
We’ve teamed up with Acro Biosystems to test if their ActiveMax μBeads can be a good cell-free off-t...
Read more -
White paper: A Change to the CTD...
Upcoming changes to the CTD framework will reshape how CMC information is structured and managed. Ou...
Read more -
Western Sweden joins forces to strengthen Swedish...
CCRM Nordic is proud to be one of the organizations signing the joint declaration of intent to stren...
Read more -
Quarter in Review: A High-Momentum Start to...
We are excited to share our quarterly reflection on what has been a dynamic start to 2026 at CCRM No...
Read more -
Upcoming Events & Where to Meet Us
Explore our upcoming events to see where the CCRM Nordic team will be attending and how you can conn...
Read more -
ATMP Mini‑Symposium 2026: Third Edition Heads to...
The ATMP Mini‑Symposium 2026 will take place on 19 May 2026 (12:00–17:00) at Lund University. It aim...
Read more
Linkblock with extra info
We can assist with individual unit operations and analytical methods or develop end-to-end manufacturing processes with all associated analytics.
- Market and IP Services We can assist with individual unit operations and analytical methods or develop end-to-end manufacturing processes with all associated analytics.
- Process and Analytical Development We can assist with individual unit operations and analytical methods or develop end-to-end manufacturing processes with all associated analytics.
- Labs and infrastracture We can assist with individual unit operations and analytical methods or develop end-to-end manufacturing processes with all associated analytics.
Logotype section
We can assist with individual unit operations and analytical methods or develop end-to-end manufacturing processes with all associated analytics.
Pagelinks section
-
Title for pagelink
Located adjacent to our offices in GoCo House, our interim 200 m2 lab is equipped to handle process and analytical development projects. This facility allows us to de-risk and optimize manufacturing workflows in preparation for future GMP translation.
Market and IP Services -
Title for pagelink
Located adjacent to our offices in GoCo House, our interim 200 m2 lab is equipped to handle process and analytical development projects. This facility allows us to de-risk and optimize manufacturing workflows in preparation for future GMP translation.
Manufacturing -
Title for pagelink
Located adjacent to our offices in GoCo House, our interim 200 m2 lab is equipped to handle process and analytical development projects. This facility allows us to de-risk and optimize manufacturing workflows in preparation for future GMP translation.
Read more
Klementina Österberg
Chief Executive Officer, GU Ventures
Klementina Österberg is the CEO of GU Ventures, a top ranked university-based incubator and seed investor that is a holding company wholly owned by the Swedish state and managed by the University of Gothenburg. She has participated in the development of many startups, of which 15 have been listed on a stock exchange, and built new investment vehicles. She is chairperson of Vasa Angels, GOKAP Invest, Destination Invest, and member of the boards of several startups within pharma, medtech etc. She is also chairperson of the association for the Swedish university based holding companies, FUHS. Thanks to these achievements, she has been acknowledged as the “Annual Financial Profile” and “Growth adviser” to the Volvo Group Connected Solutions. She has also been actively establishing the West-Swedish incubator community collaboration and GoWest, the Nordic Venture Capital Forum together with her colleagues. Previously, she worked for Venture Cup, Volvo Cars, DaimlerChrysler and Geveko Industries.
Michael Israels
Chief Financial Officer, CCRM
Michael Israels is the Chief Financial Officer of CCRM. Prior to joining CCRM, Michael was a Management Consultant at Ernst & Young LLP, President of BEST Funds, a venture capital company, and CEO of Convexus Managed Services Inc., a start-up fund administration company.
As CFO, Michael is responsible for overseeing operational effectiveness and efficiency at CCRM, the creation and development of start-up regenerative medicine companies, and the sourcing of risk capital.
Regina Fritsche-Danielson
SVP and Head of Early CVRM, Biopharmaceuticals R&D, AstraZeneca
Associate Professor, Dr Regina Fritsche-Danielson is accountable for research and early clinical development up to Ph3 in cardiovascular, renal and metabolic diseases. Regina received her PhD in Cardiovascular Physiology/Pharmacology at the University of Göteborg in 1993. After her postdoc, Regina was awarded a prestigious grant from the Swedish Natural Research Foundation (NFR). During her academic years Regina lead a research group and worked at the University of Göteborg, University of Ottawa, University of Queensland and University of Nevada. Regina joined AstraZeneca in 2001 and has held various leadership positions and led drug projects in discovery and development phases.
Regina is a steering committee member of several strategic research collaborations including Silence Therapeutics, Ionis Therapeutics, Procella therapeutics as well as the British Heart Foundation Centre for Research Excellence (CRE) Cambridge. She is also a board member of FluiCell AB, OligoNova and CCRM Nordic and she is an advisor for MRC Institute of Metabolic Science strategy University of Cambridge.
Text columns section
CMC Strategy Is Central to ATMP Success
To develop a market-viable ATMP, a regulatory-compliant and future-proof CMC package is essential. It enables progress into clinical trials and, eventually, marketing authorisation.
A CMC gap analysis identifies deficiencies and risks in your development program. It helps you to focus resources, reduce delays, and ensure that product development progresses cost-efficiently and at the right regulatory pace.
CMC Strategy Is Central to ATMP Success
To develop a market-viable ATMP, a regulatory-compliant and future-proof CMC package is essential. It enables progress into clinical trials and, eventually, marketing authorisation.
A CMC gap analysis identifies deficiencies and risks in your development program. It helps you to focus resources, reduce delays, and ensure that product development progresses cost-efficiently and at the right regulatory pace.
Text columns section
CMC Strategy Is Central to ATMP Success
To develop a market-viable ATMP, a regulatory-compliant and future-proof CMC package is essential. It enables progress into clinical trials and, eventually, marketing authorisation.
A CMC gap analysis identifies deficiencies and risks in your development program. It helps you to focus resources, reduce delays, and ensure that product development progresses cost-efficiently and at the right regulatory pace.
CMC Strategy Is Central to ATMP Success
To develop a market-viable ATMP, a regulatory-compliant and future-proof CMC package is essential. It enables progress into clinical trials and, eventually, marketing authorisation.
A CMC gap analysis identifies deficiencies and risks in your development program. It helps you to focus resources, reduce delays, and ensure that product development progresses cost-efficiently and at the right regulatory pace.
CMC Strategy Is Central to ATMP Success
To develop a market-viable ATMP, a regulatory-compliant and future-proof CMC package is essential. It enables progress into clinical trials and, eventually, marketing authorisation.
A CMC gap analysis identifies deficiencies and risks in your development program. It helps you to focus resources, reduce delays, and ensure that product development progresses cost-efficiently and at the right regulatory pace.
h1- CMC Strategy Is Central to ATMP Success
h2- CMC Strategy Is Central to ATMP Success
h3- CMC Strategy Is Central to ATMP Success
h4- CMC Strategy Is Central to ATMP Success
h5- CMC Strategy Is Central to ATMP Success
h6- CMC Strategy Is Central to ATMP Success
To develop a market-viable ATMP, a regulatory-compliant and future-proof CMC package is essential. It enables progress into clinical trials and, eventually, marketing authorisation.
A CMC gap analysis identifies deficiencies and risks in your development program. It helps you to focus resources, reduce delays, and ensure that product development progresses cost-efficiently and at the right regulatory pace.
A CMC gap analysis identifies deficiencies and risks in your development program. It helps you to focus resources, reduce delays, and ensure that product development progresses cost-efficiently and at the right regulatory pace.
For ATMPs, which are inherently complex and variable, developing a robust control strategy is critical. Using elements of Quality by Design (QbD) improves product and process understanding, supports comparability when changes occur, and strengthens quality, safety and efficacy across the product lifecycle.
- For ATMPs, which are inherently complex and variable, developing a robust control strategy is critical.
- Using elements of Quality by Design (QbD) improves product and process understanding.
- Supports comparability when changes occur, and strengthens quality
- Safety and efficacy across the product lifecycle.
For ATMPs, which are inherently complex and variable, developing a robust control strategy is critical. Using elements of Quality by Design (QbD) improves product and process understanding, supports comparability when changes occur, and strengthens quality, safety and efficacy across the product lifecycle.
- For ATMPs, which are inherently complex and variable, developing a robust control strategy is critical.
- Using elements of Quality by Design (QbD) improves product and process understanding.
- Supports comparability when changes occur, and strengthens quality
- Safety and efficacy across the product lifecycle.
Text rows
Text rows
For ATMPs, which are inherently complex and variable, developing a robust control strategy is critical. Using elements of Quality by Design (QbD) improves product and process understanding, supports comparability when changes occur, and strengthens quality, safety and efficacy across the product lifecycle.
USP section
Whether you’re an academic team or an early-stage company, we offer multiple ways to collaborate. Get in touch to learn how we can support your development journey.
USP item
No ATMP-related project is too small for us to consider. Let us know what you have in mind and we’ll try to guide you.
USP item
Although we have limited capabilities in this area right now, we’re constantly scoping for interesting technologies that align with our strategic plan.
USP item
We can either apply as a partner, a service provider or endorse grants. Let us know if you have a grant in mind, otherwise we might have one.
CTA box
Video section
CCRM Nordic is based on the successful model developed by CCRM in Toronto. We maintain close ties with our Canadian counterpart and collaborate through shared learnings, aligned methods and strategic dialogue — giving Nordic ATMP developers access to a broader international ecosystem.